ClinicalTrials.gg
RecruitingNCT07741565Updated Nov 12, 2026

Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)

An Early Phase 1 interventional study of Nivolumab-IRDye800 in HNSCC, SCC - Squamous Cell Carcinoma and Oral Cancer, sponsored by Vanderbilt-Ingram Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Vanderbilt-Ingram Cancer Center · Early Phase 1, Interventional, and Diagnostic

How we know · 2 judgments

Updated Nov 12, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Squamous Cell Carcinoma of Head and Neck by Vanderbilt-Ingram Cancer Center — 8 open to participants now, 9 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · Vanderbilt-Ingram Cancer Center.

Planned enrollment
13th of 13
18 · median 40
Started
2026
with 3 others
Phase 1
8 of 24
7 open now
Registered
24th of 24
by date

Among the 24 studies in Squamous Cell Carcinoma of Head and Neck by Vanderbilt-Ingram Cancer Center, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2026, is one of 8 in phase 1, and was the 24th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

8 of the 24 studies in Squamous Cell Carcinoma of Head and Neck by Vanderbilt-Ingram Cancer Center are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Squamous Cell Carcinoma of Head and Neck by Vanderbilt-Ingram Cancer Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether intratumoral (injected directly into the tumor) fluorescently labeled nivolumab (nivo800) is safe for adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled to undergo surgery. Researchers also want to learn how well nivo800 travels to nearby lymph nodes and whether it can be used to study immune responses in and around the tumor.

The main questions it aims to answer are:

  • Is intratumoral nivo800 safe and well tolerated in patients with HNSCC?
  • How much of the injected nivo800 reaches and remains in nearby lymph nodes, and how is drug delivery related to immune and tumor responses?

Participants will:

  • Receive a first injection of nivo800 directly into the tumor approximately 14-21 days before surgery.
  • Receive a second injection of nivo800 directly into the tumor approximately 1-3 days before surgery.
  • Have physical exams, vital signs assessments, blood tests, and safety monitoring during the study.
  • Undergo their planned standard-of-care surgery, during which tumor and lymph node tissues will be collected for research analyses.
  • Provide blood samples and complete follow-up assessments to evaluate side effects and study drug distribution.
03

Conditions studied

  • HNSCC
  • SCC - Squamous Cell Carcinoma
  • Oral Cancer

Keywords

  • Nivo800
  • Fluorescent Guided Surgery
  • Head and Neck Cancer
  • SCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have proven HNSCC.
  2. Planned to undergo surgical excision.
  3. Age ≥ 18 years.
  4. Adequate hematologic and end-organ function appropriate for surgical resection and anesthesia (within 30 days of infusion).
  5. Written .

Exclusion criteria

Exclusion Criteria:

  1. Patients not eligible for SOC surgical resection
  2. Active or history of disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis with the following exceptions:

    • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.
    • Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided if all the following conditions are met:
    • Rash must cover \< 10% of body surface area
    • Disease is well controlled at baseline and requires only low-potency topical
    • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency oral corticosteroids within the previous 12 months.
  3. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.

    • History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  4. Significant cardiovascular disease (such as Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 6 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
  5. Severe unresolved infection within 4 weeks prior to initiation of study treatment.
  6. Prior allogeneic stem cell or solid organ transplantation
  7. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  8. Chronic treatment with systemic medication in excess of physiologic maintenance doses of corticosteroids (>10 mg/day of prednisone or equivalent) (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-a agents), with the following exceptions:

    • Patients who received acute, systemic immunosuppressant medication or a dose of systemic immunosuppressant medication are eligible for the study.
    • Physiologic corticosteroid replacement therapy at doses ≤ 10 mg/day of prednisone or equivalent for adrenal or pituitary insufficiency and in the absence of active autoimmune disease is permitted.
    • Patients with asthma that requires intermittent use of bronchodilators, inhaled steroids, or local steroid injections may participate.
    • Patients using topical, ocular, intra-articular, or intranasal steroids (with minimal systemic absorption) may participate.
    • Brief courses of corticosteroids for prophylaxis (e.g., contrast dye allergy) or study treatment-related standard pre-medication are permitted.
  9. Pregnant or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final administration of study treatment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Cohort 1 - Nivo800 (2.5 mg/cm)

    Participants in Cohort 1 will receive two intratumoral injections of nivolumab-IRDye800 (nivo800) at a dose of 2.5 mg per centimeter of greatest tumor diameter. The first injection will be administered approximately 14-21 days before planned surgical resection, and the second injection will be administered approximately 1-3 days before surgery. Injections will be performed directly into the tumor using a multi-quadrant technique when feasible to maximize drug distribution within the tumor.

    Drug: Nivolumab-IRDye800

  • Experimental
    Expansion Cohort - Nivo800 (5 mg/cm)

    Participants in the Expansion Cohort will receive two intratumoral injections of nivolumab-IRDye800 (nivo800) at a dose of 5 mg per centimeter of greatest tumor diameter. The first injection will be administered approximately 14-21 days before planned surgical resection, and the second injection will be administered approximately 1-3 days before surgery. Injections will be delivered directly into the tumor using a multi-quadrant technique when anatomically feasible to maximize intratumoral distribution.

    Drug: Nivolumab-IRDye800

Interventions

  • DrugNivolumab-IRDye800

    Nivolumab-IRDye800 (nivo800) is an investigational fluorescent imaging agent consisting of the anti-PD-1 monoclonal antibody nivolumab conjugated to IRDye800CW, a near-infrared fluorescent dye. Unlike standard therapeutic nivolumab, nivo800 is administered intratumorally rather than intravenously and is used to evaluate local drug distribution, lymphatic trafficking, and molecular imaging in patients with head and neck squamous cell carcinoma. Participants receive two preoperative intratumoral injections of nivo800 at a dose level determined by study cohort (2.5 mg/cm or 5 mg/cm of greatest tumor diameter).

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Determine the safety nivo800 administered intratumorally.

    Number of Grade ≥ 2 adverse events (AE) determined to be clinically significant and considered definitely or probably related to nivo800.

    Time frame: Up to 30 Days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — We do not plan to share individual participant data from this phase 1 study due to its exploratory nature with a new drug. Sharing individual-level data at this stage could compromise participant confidentiality and may not yield meaningful insights given the preliminary scope of the study.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2031, 59 months after the start.

Of 116 non-industry phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 61. This study's planned 59 months is above that.

Counting every sponsor, half of 272 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Aug 3, 2026
StartActual
Oct 30, 2026was Sep 2026
Primary completionEst.
Sep 30, 2031
CompletionEst.
Sep 30, 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
1 site added — first site in United States
Show site
  • Vanderbilt University Medical Center · Nashville, United States
Oct 19, 2026
Start date
Sep 30, 2026→Oct 30, 2026 (actual)
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Start date Sep 30, 2026→Oct 30, 2026 (now actual)
  2. Oct 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Vanderbilt University Medical Center · Nashville, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07741565
Responsible party
Kenji Kobayashi (Assistant Professor: Otolaryngology, Vanderbilt University Medical Center) — Principal investigator
First posted
Aug 3, 2026
Start date
Oct 30, 2026
Primary completion
Sep 30, 2031 (estimated)
Completion
Sep 30, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Makenna L Brown, MD
Contact
makenna.l.brown@vumc.org
615-421-4370
Nicole L Jones, MD
Contact
nicole.l.jones@vumc.org
615-936-2807
Kenji Kobayashi, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion